검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-TNF Drug (Anti-TNF Drug) Schneider Children's Medical Cente…·Crohn Disease ORR 1.8%·t½ 248.54 days |
|---|---|
Overview Program | Anti-TNF Drug |
Overview Company | Schneider Children's Medical Center, Israel |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Crohn Disease |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeted disruption of the physiological pathway |
MoA Biomarker | biomarkers, and integrating and disseminating effective interventions into community and clinical practice to |
PK/PD Half-life | 248.54 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.. Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment through targeted disruption of the physiological pathways that maintain… |
Clinical Primary efficacy | ORR 1.8% |
Clinical ORR | 1.80% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-TNF Drug (Anti-TNF Drug) Schneider Children's Medical Cente…·Crohn Disease ORR 1.8%·t½ 248.54 days |
|---|---|
Overview Program | Anti-TNF Drug |
Overview Company | Schneider Children's Medical Center, Israel |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Crohn Disease |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeted disruption of the physiological pathway |
MoA Biomarker | biomarkers, and integrating and disseminating effective interventions into community and clinical practice to |
PK/PD Half-life | 248.54 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.. Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment through targeted disruption of the physiological pathways that maintain… |
Clinical Primary efficacy | ORR 1.8% |
Clinical ORR | 1.80% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교